+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder



Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder



European Urology 57(5): 766-773



Intravesical chemotherapy and bacillus Calmette-Guérin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial, especially in intermediate-risk patients. The aim of the study was to compare the long-term efficacy of BCG and epirubicin. From January 1992 to February 1997, 957 patients with intermediate- or high-risk stage Ta T1 urothelial bladder cancer were randomized after transurethral resection to one of three treatment groups in the European Organization for Research and Treatment of Cancer Genito-Urinary Group phase 3 trial 30911. Patients received six weekly instillations of epirubicin, BCG, or BCG plus isoniazid (INH) followed by three weekly maintenance instillations at months 3, 6, 12, 18, 24, 30, and 36. End points were time to recurrence, progression, distant metastases, overall survival, and disease-specific survival. With 837 eligible patients and a median follow-up of 9.2 yr, time to first recurrence (p<0.001), distant metastases (p=0.046), overall survival (p=0.023), and disease-specific survival (p=0.026) were significantly longer in the two BCG arms combined as compared with epirubicin; however, there was no difference for progression. Three hundred twenty-three patients with stage T1 or grade 3 tumors were high risk, and the remaining 497 patients were intermediate risk. The observed treatment benefit was at least as large, if not larger, in the intermediate-risk patients compared with the high-risk patients. In patients with intermediate- and high-risk stage Ta and T1 urothelial bladder cancer, intravesical BCG with or without INH is superior to intravesical epirubicin not only for time to first recurrence but also for time to distant metastases, overall survival, and disease-specific survival. The benefit of BCG is not limited to just high-risk patients; intermediate-risk patients also benefit from BCG. This study was registered with the US National Cancer Institute clinical trials database [protocol ID: EORTC-30911]. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=77075&version=HealthProfessional&protocolsearchid=6540260.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054164536

Download citation: RISBibTeXText

PMID: 20034729

DOI: 10.1016/j.eururo.2009.12.024


Related references

Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. European Urology 59(6): 1065, 2011

Long-term efficacy results of EORTC GU group study 30911 comparing epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage Ta T1 bladder carcinoma. 2008

Long-term efficacy results of EORTC GU group study 30911 comparing epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage TA T1 papillary carcinoma of the bladder. European Urology Suppl.s 7(3): 298, 2008

Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European organization for research and treatment of cancer genito-urinary group randomized phase III trial. Journal of Urology 166(2): 476-481, 2001

Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). European Urology 59(3): 438-446, 2011

The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. European Urology 66(4): 694-701, 2015

Prognostic factors in patients with intermediate and high risk stage TA T1 papillary carcinoma of the bladder treated with maintenance epirubicin or maintenance bacillus Calmette-Guerin. Results of eortc gu group study 30911. European Urology Suppl.s 7(3): 178, 2008

Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. European Urology 65(1): 69-76, 2014

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Journal Of Urology. 156(2 Part 1): 372-376, 1996

Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 82(2): 290-296, 1991

The side effects of Bacillus Calmette-Guerin in the treatment of TA T1 bladder cancer do not predict its efficacy Results from an EORTC genito-urinary group phase III Trial. European Urology Suppl.s 2(1): 191, 2003

Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. Medicine 95(3): E2572, 2016

Maintenance Bacillus Calmette-Guerin for TA, T1 bladder cancer is not associated with increased toxicity Results from an EORTC genito-urinary group phase III Trial. European Urology Suppl.s 2(1): 190, 2003

A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. European Urology 52(5): 1398-1406, 2007

Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder. Journal of Urology 153(3): 929-933, 1995